Member Info for Steadydanny

Just read the words and see what has unfurled. I reckon we are onto a RNS re FLT3 re potential for licensees.
London, UK, 5 May 2021

Sareum Holdings (SAR): Treading the TYK2 trail

Kinase inhibitor specialist Sareum develops small molecule therapeutics with application in oncology and autoimmune disease areas. Lead asset SDC-1801 targets the autoimmune space and is nearing an inflection point, with a planned clinical trial application (CTA) filing in mid-2021 and clinical progression in Q421. The other candidate, SDC-1802, is focused on cancer and holds first-in-class promise with value to be unlocked with clinical validation. The out-licensed assets, SRA737 and FLT3+Aurora kinase, are currently de-prioritised but offer upside potential on revived activity.
So 737 which we was seen as de-prioritised but the Q and A response was rather marvellous. So FLT3 next?
And then 1802 patent update and this extract....
The other candidate, SDC-1802, is focused on cancer and holds first-in-class promise with value to be unlocked with clinical validation.

Didn't Tim in Q and A mention they were not concerned about not being 1st to market for TYK2 applications ad we will be. Which has potential for multiple diseases.
We as per our corporate objectives stipulate licensing. I'm imo reckoning on some very significant updates here. And PH are no coincidence.
It looks good to me.

Hi smart inv this is re deals for sareum in place in November 2020 RNS. Also please note recent Q and A re the success of 737 at Sierra. Which was more than encouraging.

Overview of SRA737

SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.  

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK.

SRA737 was licensed by CPF to Sierra in September 2016 for up to $328.5 million in developmental, regulatory and commercial milestones, plus royalties on the net sales of any product successfully developed. Sareum was eligible to receive 27.5% of the economics equating to up to $88 million in milestone payments, plus sales royalties, as SRA737 advances.
So the wheels are definitely in motion re income.
I'd also just mention the wording in our RNSs re FLT3. We were building up 737 in our reports steadily and then boom the great success it has shown. I am waiting for a blindsider RNS to come re FLT3 re us open to licensees given we got back the drug with all data as they couldn't achieve I believe dosage or similar. And as pointed out they are a shareholder here.
Lots of further news incoming I expect.

Seriously just look at my previous previous posts re 737. Called it by reading the RNSs with a microscope and others jump on it as if it is their opinion.
I was ridiculed believing 737 had potential.
Irrespective I still see TYK2 as rather marvellous also. As I mentioned from the q and a a game changer.
Holding my own as always.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Been banging on about this.
It's happening

HBD totally agree. Atleast some of us partook in the Q and A. Everything was politely positive without giving away too much.
That's what estute BODS do.

Casa re 737 and negotiations this is our update re 25th May RNS

Sareum is not aware at this time of any additional updates from Sierra Oncology (“Sierra”) regarding its plans for the further development of SRA737. The Company is, however, encouraged by the appointment of Mark Kowalski, MD, PhD as Chief, Research and Early Development, to focus on, among other things, the ongoing evaluation of development opportunities for Sierra’s pipeline assets. Furthermore, Sareum continues to believe that the licensing agreement amendment signed in November 2020 between CRT Pioneer Fund and Sierra will help expedite the SRA737 development programme.

The Company looks forward to providing a more comprehensive business update at the time of the Full-year Results, expected in October 2021.

Well since then 737 mentions have been consistently getting more verbiage in Sareum updates and Sierra have added the AZ drug to their pipeline and those who listened to the recent Q and A Tim when discussing the 100% effectiveness re 737 and lung cancer was obviously very excited.
The increase in chair squeaking spoke volumes!
But his near final mention re TYK2 was rather memorable.
I wrote down what I could but in a nutshell I got.......we are not concerned about being 1st to market for TYK2 applications as we will be 1st and this has the potential for multiple diseases.
All best Steadydanny

Hi Bobby. Regards the takeover discussions on here this is from our last trading update from our Chairman and CEO

In terms of business development, we are continuing to keep potential partners informed of our progress with a view to securing commercial licences for our TYK2/JAK1 programmes that balance cost and risk with maximising shareholder value. We will, as usual, keep shareholders updated in this regard as appropriate.

So personally I see licenses with upfront payments and then milestone payments on progress and then royalties. Possibly with our BOD acting as consultants with NDAs in place. I also think those other names on the Submarine Patent could possibly have some form of sub contractor benefit to Sareum.
That's my thoughts.

Mike fyi
CHAIRMAN'S AND CEO'S STATEMENT

Sareum continues to make progress advancing its proprietary, selective dual tyrosine kinase 2 ("TYK2") / Janus kinase 1 ("JAK1") inhibitors, SDC-1801 and SDC-1802, through preclinical development.

We are pleased to report that we are approaching an important milestone with SDC-1801, the start of human clinical development, targeting autoimmune diseases.

As noted in the Company's Trading Update of 19 August 2021, we expect to complete the toxicology studies required for this phase of the preclinical programme for SDC-1801 by the end of 2021 and have initiated the process to manufacture drug product for clinical trials.

We made the decision to develop a capsule formulation of SDC-1801 for these first-in-human trials rather than orally dosed solutions or suspensions, which requires additional time, but the Board believes will add value to the programme and remove the need to develop capsules at a later stage

When they say initiated drug trials it as if the media response was lost on sareums loss. It wasn't a loss! It was paid for r and d! Ongoing.

Seriously am I alone here. The nonsense posts are draining me. I'm bloody well going to ask Tim et al for a marketing job at sareum.

James I like the poem by Rudyard Kipling it starts with this. My mantra in life.
IF by RK
If you can keep your head when all doubt you
Are losing theirs and blaming it on you
If you can trust yourself when all men doubt you
But make no allowance for their doubting too
If you can wait and not be tired by waiting
Or being lied about, don't deal in lies
Or being hated, don't give way to hating
And yet don't look too good, nor talk too wise

I think the fair levelled discussion here prior to the shake today would serve any investor to take a breather, remind themselves why they invested, not get drawn into obvious baiting due to exercised warrants that are being banded about as directors jumping ship.
They are trying their level best to create distrust here. Yet no scientific factual backup to support the hyena comments.
Looks good to me.

Mike the deferred amount of £150k was for all employees over 20 months of deferred salary!
They actually took one for the team aka sareum to keep progressing but reducing overheads with the I suspect knowledge we are onto something marvellous.
Ever seen a BOD on AIM do that before?
Yesterday's Q and A was brilliant.
HNWIs would not invest unless they were comfortable with the BOD. One of them paid £1m @ 8.25p.

Salary Deferral Scheme

The salary deferral scheme, as announced by the Company on 17 December 2019 and updated on 1 July 2020, will end in August 2021, with a total of £155k, representing all amounts outstanding, being settled in cash, following the significant c.£4.5m improvement in the Company's financial position arising from the recent share subscriptions and warrant exercise.

They are not going to shaft the HNWIs.
This is a shake. Notice the hyenas wading in who never post on factual reported updates!?
They probably think a kinase inhibitor is under a car bonnet.

That was my thought HBD.

Can they be forward sold? Maybe because there are some fill orders which were unable to be filled before ?

Great spot HBD. And as Ahfam pointed out Peel Hunts relationship with Sareum is not just as our recently appointed dual broker with immediate effect, they are also listed as shareholders in Sareum.
Speaks volumes, they are now one of our brokers, have a holding in Sareum, and the cracking news yesterday re 737,1801, 1802 and Tim's non concern of TYK2 competion.....tick tock tick tock

Yes exactly mafuta my post end of October

Also worth noting the amount of our RNS re PH that involves discussing 737. About two thirds and note the initial paragraph re generate value
About Sareum through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage......so this...pre clinical or early clinical trials!!

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Best wishes to all and I feel we have significant news coming that will become apparent to ....maybe the world.?
Think we for an update today rw 737!?
All good. Just waiting for the brakes to be released re ap and mc.

Hi HBD. Thank-you for clarifying. I thought it was just me hearing the response re submarine patent with distinct chair squeaking. ts like they kept it second to last re responses. Last one being not being concerned re TYK2 competition.
I got outbid on a Gilchrest captains chair at auction. Im wondering if Tim has one. Lovely chairs. The chairs do squeak. Candle wax stops the squeaks.
When the market wakes up to this we are definitely worth what RMM posts.
Very best regards Steadydanny

Evening HBD. Now I am at a loss here.
My question/s were
If possible are you able to elaborate further on the Submarine Patent and its potential for Sareum? Could I further offer a question regards the Submarine patent and if it has progressive indications towards
A 1801
B 1802
C FLT3
D SRA737
Or all of the above. And another ongoing research.

Appreciate a bit of help here as I have not relistened to the presentation as the chair squeaking regarding this question tied in with similar questions seemed to increase and the response seemed muffled. Almost like the chair squeaking was as if someone was excited. All I got was that the submarine patent was not relevant to FLT3. Maybe missed the other molecules being dismissed re relevance to the submarine patent.
Most probably reading too deep and my hearing ageing.
Appreciate your thoughts.
And hasn't 737 shown its potential!!
Best regards HBD.
Steadydanny

All very positive
JAK inhibitors market 2020 =£18b estimated by 2026 £320b. Massive increase in market potential.
1801 - advancing with our funds as early clinical trials = less worth, later positive development = greater worth. They seemed confident with the findings to continue and that will raise further potential partner awareness and value.
1802 as he said will develop rapidly due to the almost identical properties to 1801 so just box ticking and value increase.
737 he was very excited re the 100% lung cancer result when showing the graph. And it's been noteable that any recent company update has given considerable reference to 737 since the new pipeline guy at Sierra.
In general his near final response re TYK2 was very positive and had no competition concerns.
I reckon the silence of PH not publicising our new immediate relationship is that we have something incoming very soon and they will do an update press release showing how great their recent 120M IPO is to be invested in given new customer additions.
Looking very very good to me.

He definitely was excited re the 100% lung cancer response on the chart re 737!!

Just got here from the webinar and was going to suggest we chip in and buy him some 3 in 1 oil for the chair. Soooo funny I thought it was just me.
Anyway TYK2 re one of the closing responses re first to market and the massive range of diseases it has potential for definitely was the hilight for me.